KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Share-based Compensation (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Share-based Compensation for 13 consecutive years, with $11.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 24.42% year-over-year to $11.5 million, compared with a TTM value of $44.9 million through Dec 2025, up 21.55%, and an annual FY2025 reading of $44.9 million, up 21.55% over the prior year.
  • Share-based Compensation was $11.5 million for Q4 2025 at Travere Therapeutics, up from $11.3 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $13.5 million in Q1 2023 and bottomed at $7.0 million in Q3 2021.
  • Average Share-based Compensation over 5 years is $9.7 million, with a median of $9.5 million recorded in 2022.
  • The sharpest move saw Share-based Compensation soared 73.2% in 2022, then fell 29.14% in 2024.
  • Year by year, Share-based Compensation stood at $7.4 million in 2021, then increased by 26.04% to $9.3 million in 2022, then dropped by 12.4% to $8.1 million in 2023, then rose by 13.14% to $9.2 million in 2024, then grew by 24.42% to $11.5 million in 2025.
  • Business Quant data shows Share-based Compensation for TVTX at $11.5 million in Q4 2025, $11.3 million in Q3 2025, and $10.6 million in Q2 2025.